AHA 2015
Study Provides Insight into Antithrombotic Tx Reintroduction After Dabigatran Reversal
Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.
Your search for dabigatran returned 116 results
News
Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
Drug Monograph Updates
June 2014 Recap of Drug Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list).
News
Nearly 25% of A-fib Patients Prescribed Anticoagulants May Not Need Them
As many as 25 percent of patients with atrial fibrillation (AF) at the lowest risk for stroke may be taking oral anticoagulants despite current guidelines, according to a research letter published online in JAMA Internal Medicine.
Drugs in the Pipeline
FDA Accepts sNDA for New Pradaxa Indication
Boehringer Ingelheim announced that the FDA has accepted for filing the supplemental New Drug Application (sNDA) for Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip replacement surgery.
Uncategorized
FDA Updates on Bleeding Risk of Pradaxa
The FDA's recommendations regarding Pradaxa remain unchanged following the November 2012 Mini-Sentinel evaluations. Findings showed that bleeding rates associated with Pradaxa use during the period did not appear to be higher than those associated with warfarin.
News
Racial/Ethnic Disparities Seen in Anticoagulant Initiation for A-Fib
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Drug News
Study: Direct Oral Anticoagulants Have Distinct Bleeding Profiles
Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.
Drug News
Compression Device Noninferior to Meds Post-Arthroplasty
For patients undergoing lower-extremity arthroplasty, a mobile compression device is noninferior to pharmacological protocols for the prevention of venous thromboembolism.
